Pacific Biosciences of California, Inc. (PACB)

Market Cap	369.77M
Revenue (ttm)	200.52M
Net Income (ttm)	-306.74M
Shares Out	267.95M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,883,683
Open	1.360
Previous Close	1.360
Day's Range	1.300 - 1.420
52-Week Range	1.250 - 14.550
Beta	1.83
Analysts	Buy
Price Target	7.77 (+463.04%)
Earnings Date	May 9, 2024

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified D...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 796
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB

Financial Performance

In 2023, PACB's revenue was $200.52 million, an increase of 56.29% compared to the previous year's $128.30 million. Losses were -$306.74 million, -2.39% less than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $7.77, which is an increase of 463.04% from the latest price.

Price Target

$7.77

(463.04% upside)

Analyst Consensus: Buy